Aleph-4
Pharmaceutical compound
From Wikipedia, the free encyclopedia
Aleph-4, or ALEPH-4, also known as 4-isopropylthio-2,5-dimethoxyamphetamine, is a psychedelic drug of the phenethylamine, amphetamine, and DOx families.[1] It is one of the Aleph series of compounds.[1]
- None
| |
 | |
| Clinical data | |
|---|---|
| Other names | ALEPH-4; DOT-4; 4-Isopropylthio-2,5-dimethoxyamphetamine; 2,5-Dimethoxy-4-isopropylthioamphetamine; 4-iPrS-DMA |
| Routes of administration | Oral[1] |
| Drug class | Serotonergic psychedelic; Hallucinogen |
| ATC code |
|
| Pharmacokinetic data | |
| Duration of action | 12–20 hours[1] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C14H23NO2S |
| Molar mass | 269.40 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
In his book PiHKAL (Phenethylamines I Have Known and Loved), Alexander Shulgin lists Aleph-4's dose as 7 to 12 mg orally and its duration as 12 to 20 hours.[1] The effects of Aleph-4 have been reported to include closed-eye imagery, enhanced visual appreciation, emotional changes, and physical side effects and toxicity indications, among others.[1] One of the reports remarked that it was "one of the most profound and deep learning experiences" they had had.[1] However, Shulgin was unwilling to push the dose higher than 12 mg due to toxicity concerns.[1]
The chemical synthesis of Aleph-4 has been described.[1]
Aleph-4 was first described in the scientific literature by Shulgin, David E. Nichols, Peyton Jacob III, and other colleagues in 1978.[2] Subsequently, it was described in greater detail by Shulgin in PiHKAL in 1991.[1] The drug was encountered as a novel designer drug in Japan in 2009.[3][4] It is a Schedule I controlled substance in the United States as an isomer of 2C-T-7.[5] The drug is also a controlled substance in Canada under phenethylamine blanket-ban language.[6]